Supplementary Table 4. Clinical Characteristics of Subjects in Groups According to TG Levels.
| Variables | Total (n= 198) | TG ＜150 mg/dL (n= 127) | TG ≥ 150 mg/dL (n= 71) | P value |
|---|---|---|---|---|
| Age, yr | 64±8 | 65±8 | 62±9 | 0.01 |
| Gender, men/women | 161/37 | 99/28 | 62/9 | 0.10 |
| Body mass index, kg/m2 | 25.9±4.2 | 25.6±4.1 | 26.6±4.2 | 0.10 |
| Systolic blood pressure, mmHg | 133±18 | 134±18 | 131±16 | 0.43 |
| Diastolic blood pressure, mmHg | 74±10 | 74±11 | 75±10 | 0.75 |
| Heart rate, bpm | 66±12 | 66±11 | 67±11 | 0.88 |
| Total cholesterol, mg/dL | 166±30 | 161±28 | 175±31 | 0.002 |
| TG, mg/dL | 147±111 | 93±28 | 243±137 | N/A |
| HDL-C, mg/dL | 50±14 | 53±14 | 44±12 | ＜0.001 |
| LDL-C, mg/dL | 88±25 | 89±22 | 85±29 | 0.30 |
| sdLDL-C, mg/dL | 32.4±14.8 | 26.2±11.0 | 43.4±14.2 | ＜0.001 |
| Glucose, mg/dL | 141±45 | 134±36 | 152±56 | 0.01 |
| Hemoglobin A1c, % | 7.2±1.0 | 7.0±0.9 | 7.4±1.1 | 0.01 |
| Creatinine, mg/dL | 0.86±0.24 | 0.86±0.24 | 0.86±0.25 | 0.92 |
| eGFR, mL/min per 1.73 m2 | 71±18 | 70±19 | 72±17 | 0.41 |
| Current Smoking, n (%) | 26 (13.4) | 13 (10.3) | 13 (19.1) | 0.09 |
| Exercise habit, n (%) | 116 (60.4) | 77 (61.6) | 39 (58.2) | 0.65 |
| Alcohol drink, n (%) | 66 (34.2) | 44 (34.9) | 22 (32.8) | 0.77 |
| Medical history, n (%) | ||||
| Hypertension | 187 (94.4) | 122 (96.1) | 65 (91.6) | 0.18 |
| Previous myocardial infarction | 92 (46.5) | 56 (44.1) | 36 (50.7) | 0.37 |
| Previous angina pectoris | 111 (56.1) | 74 (58.3) | 37 (52.1) | 0.40 |
| Medications, n (%) | ||||
| Antiplatelet drugs | 193 (97.5) | 124 (97.6) | 69 (97.2) | 0.84 |
| Statins | 198 (100) | 127 (100) | 71 (100) | |
| Fibrates | 1 (0.5) | 1 (0.79) | 0 (0) | 0.45 |
| Eicosapentaenoic acids | 14 (7.1) | 10 (7.9) | 4 (5.6) | 0.56 |
| Ezetimibe | 18 (9.1) | 10 (7.9) | 8 (11.3) | 0.43 |
| ACEIs/ARBs | 144 (72.7) | 90 (70.9) | 54 (76.1) | 0.43 |
| β-blockers | 89 (44.9) | 61 (48.0) | 28 (39.4) | 0.24 |
| Calcium-channel blockers | 100 (50.5) | 68 (53.5) | 32 (45.1) | 0.25 |
| Diuretics | 31 (15.7) | 22 (17.3) | 9 (12.7) | 0.39 |
| Any-antidiabetic drugs | 165 (83.3) | 109 (85.8) | 56 (78.9) | 0.21 |
| Oral antidiabetic drugs | 149 (75.3) | 96 (75.6) | 53 (74.7) | 0.88 |
| Insulin | 33 (16.7) | 27 (21.3) | 6 (8.5) | 0.02 |
| Framingham risk score, % | 16±8 | 15±7 | 19±9 | ＜0.001 |
TG indicates triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; sdLDL-C, small dense low- density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers.